{
  "drug_name": "Cefoperazone",
  "tradename": "Cefobid, Magnamycin",
  "usage_and_dosing": {
    "general": [
      "Cefoperazone is a 3rd-generation parenteral extended-spectrum cephalosporin.",
      "Originally FDA-approved in the early 1980s but now discontinued from the US market."
    ],
    "adult_dose": {
      "usual_dose": "1-2 gm IV q12h",
      "severe_infections": "Up to 4 gm IV q12h in severe infections",
      "uncomplicated_gonococcal_urethritis": "500 mg IM as a single dose"
    },
    "pediatric_dose": {
      "dose_age_gt_28_days": "50-200 mg/kg/day (divided q8-12h) (divided q12h if age <8 days)",
      "max_day": "12 gm"
    }
  },
  "renal_adjustment": {
    "notes": "Dosage adjustment may be required in hepatic disease.",
    "half_life_normal": "1.7-2.0",
    "half_life_esrd": "No change",
    "dose_renal_function_normal": "1-2 gm IV q12h",
    "crcl_or_egfr": "No dosage adjustment for renal impairment (if GFR <18, do not exceed 4 gm/day)",
    "hemodialysis": "No dosage adjustment (AD on dialysis days)",
    "capd": "No data",
    "crrt": "No data",
    "sled": "No data"
  },
  "hepatic_adjustment": {
    "note": "Limit dosage to 2 gm/day in patients with concomitant hepatic and renal dysfunction.",
    "mild_impairment_child_pugh_a": "No dosage adjustment",
    "moderate_impairment_child_pugh_b": "No dosage adjustment",
    "severe_impairment_child_pugh_c": "Limit dosage to 2 gm/day"
  },
  "adverse_effects": [
    "Hypersensitivity reactions",
    "Anaphylaxis",
    "Stevens-Johnson syndrome, toxic epidermal necrolysis",
    "C. difficile-associated diarrhea",
    "Increased LFTs",
    "Hematologic: anemia, neutropenia, thrombocytopenia",
    "May increase INR and cause bleeding, possibly related to the MTT side chain.",
    "See Cephalosporins, Overview"
  ],
  "pregnancy_risk": {
    "fda_risk_category": "No evidence of toxicity in humans or animals",
    "lactation": "Milk concentrations low, adverse effects not expected. Monitor infant for GI toxicity.",
    "footnote": "Capital letter = Old FDA risk category; Text = New FDA risk category"
  },
  "antimicrobial_spectrum": {},
  "pharmacology": {
    "pk_pd_index": "T>MIC",
    "preparations": "Injection",
    "food_recommendation": null,
    "oral_absorption_percent": null,
    "tmax_hr": null,
    "peak_serum_conc_ug_ml": "252 (2 gm over 15 min, SD)",
    "peak_urine_conc_ug_ml": ">2200 (2 gm IV over 15 min, SD)",
    "protein_binding_percent": "87-90",
    "volume_of_distribution_vd_l": "10.2-11.3 L",
    "avg_serum_half_life_hr": "1.7-2.0",
    "elimination": "Biliary",
    "bile_penetration_percent": "Up to 100x serum conc",
    "csf_blood_percent": "No data",
    "therapeutic_levels_in_csf": "No data",
    "auc_ug_hr_ml": "No data"
  },
  "major_drug_interactions": [
      {
          "drug": "Ethanol",
          "effect": "Possible disulfiram-type reaction",
          "management": "Avoid co-administration"
      }
  ]
}
